Skip to main content

Advertisement

SpringerLink
Log in

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms of the gastrointestinal tract that are unresponsive to standard sarcoma chemotherapy. Imaging of GIST patients is done with structural and functional methods such as contrast-enhanced helical computed tomography (ceCT) and positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG). The aim of this study was to compare the prognostic power of PET and ceCT and to evaluate the clinical role of PET/CT imaging.

Methods

All patients with GIST undergoing PET or PET/CT examinations were prospectively included in this study, and the median overall survival, time to progression and treatment duration were documented. The prognostic significance of PET and ceCT criteria of treatment response was assessed and PET/CT was compared with PET and ceCT imaging. Data for 34 patients (19 male, 15 female, 21–76 years) undergoing PET or PET/CT for staging or restaging were analysed.

Results

In 28 patients, PET/CT and ceCT were available after introduction of treatment with the tyrosine kinase inhibitor imatinib mesylate (Gleevec; Novartis, Basel, Switzerland). Patients without FDG uptake after the start of treatment had a better prognosis than patients with residual activity. In contrast, ceCT criteria provided insufficient prognostic power. However, more lesions were found on ceCT images than on PET images, and FDG uptake was sometimes very variable. PET/CT delineated active lesions better than did the combination of PET and ceCT imaging.

Conclusion

Both PET and PET/CT provide important prognostic information and have an impact on clinical decision-making in GIST patients. PET/CT precisely delineates lesions and thus allows for the correct planning of surgical interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–20.

    Article  CAS  PubMed  Google Scholar 

  2. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12.

    Article  CAS  PubMed  Google Scholar 

  3. Wang X, Mori I, Tang W, Utsunomiya H, Nakamura M, Nakamura Y, et al. Gastrointestinal stromal tumors: are they of Cajal cell origin? Exp Mol Pathol 2002;72:172–7.

    Article  CAS  PubMed  Google Scholar 

  4. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211–20.

    CAS  PubMed  Google Scholar 

  5. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484–95.

    Article  CAS  PubMed  Google Scholar 

  6. Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527–32.

    PubMed  Google Scholar 

  7. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Am J Roentgenol 2002;179:1059–62.

    Google Scholar 

  8. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60–5.

    Google Scholar 

  9. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45:17–21.

    Google Scholar 

  10. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012–20.

    Article  CAS  PubMed  Google Scholar 

  11. Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von Schulthess GK. PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 2002;29:351–60.

    Article  CAS  PubMed  Google Scholar 

  12. Dizendorf EV, Treyer V, Von Schulthess GK, Hany TF. Application of oral contrast media in coregistered positron emission tomography-CT. Am J Roentgenol 2002;179:477–81.

    Google Scholar 

  13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.

    Article  CAS  PubMed  Google Scholar 

  14. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773–82.

    Article  CAS  PubMed  Google Scholar 

  15. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–65.

    Article  PubMed  Google Scholar 

  16. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–87.

    Google Scholar 

  17. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, Yonekura Y. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003;30:63–71.

    Article  CAS  PubMed  Google Scholar 

  18. Emory TS, O’Leary TJ. Prognosis and surveillance of gastrointestinal stromal/smooth muscle tumors. Ann Chir Gynaecol 1998;87:306–10.

    CAS  PubMed  Google Scholar 

  19. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–8.

    Article  CAS  PubMed  Google Scholar 

  20. Hohenberger P, Bauer S, Schneider U, Pinlk D, Dirsch O, Schuette J, Reichardt P. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Am Soc Clin Oncol 2003;22:818 (abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland

    G. W. Goerres, T. F. Hany, E. Dizendorf & G. K. von Schulthess

  2. Multidisciplinary Oncology Centre, University of Lausanne Medical Centre, Lausanne, Switzerland

    R. Stupp, F. Luthi & S. Leyvraz

  3. Department of Radiology, University of Lausanne Medical Centre, Lausanne, Switzerland

    G. Barghouth & P. Schnyder

  4. Department of Oncology, University Hospital Zurich, Zurich, Switzerland

    B. Pestalozzi

  5. International Tomography Center, Novosibirsk, Russia

    E. Dizendorf

Authors
  1. G. W. Goerres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Stupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Barghouth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. F. Hany
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Pestalozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Dizendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Schnyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Luthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. K. von Schulthess
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Leyvraz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. W. Goerres.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goerres, G.W., Stupp, R., Barghouth, G. et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32, 153–162 (2005). https://doi.org/10.1007/s00259-004-1633-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1633-7

Keywords

Search

Navigation